New trends in Clostridium difficile virulence and pathogenesis

被引:148
作者
Deneve, C. [1 ]
Janoir, C. [1 ]
Poilane, I. [2 ]
Fantinato, C. [2 ]
Collignon, A. [1 ,2 ]
机构
[1] Univ Paris Sud, Fac Pharm, EA 4043, F-92296 Chatenay Malabry, France
[2] Hop Jean Verdier, AP HP, Microbiol Serv, Paris, France
关键词
Clostridium difficile; Hypervirulent; Epidemic; 027; strain; SURFACE-LAYER PROTEINS; TOXIN PRODUCTION; ADP-RIBOSYLTRANSFERASE; MOLECULAR ANALYSIS; EPIDEMIC; GENE; STRAINS; RISK; DIARRHEA; BINDING;
D O I
10.1016/S0924-8579(09)70012-3
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The disease spectrum caused by Clostridium difficile infection ranges from antibiotic-associated diarrhoea to life-threatening clinical manifestations such as pseudomembranous colitis. C. difficile infection is precipitated by antimicrobial therapy that causes a disruption of the normal colonic microbiota, predisposing to C. difficile intestinal colonisation. The pathogenicity of C. difficile is mediated by two exotoxins, TcdA and TcdB, both of which damage the human colonic mucosa and are potent cytotoxic enzymes. C. difficile must first be implanted in the gut and attach to epithelial cells, which are protected by a layer of dense mucus. Confirmed and putative accessory virulence factors that could play a role in adherence and intestinal colonisation have been identified and include proteolytic enzymes and adhesins. Recently, the epidemiology of C. difficile infection has radically changed and an increased incidence is associated with outbreaks in North America and Europe. Several reports suggest that disease severity is increasing to include sepsis syndrome and toxin megacolon. Elderly, debilitated patients in hospitals and nursing homes are particularly vulnerable. A hypervirulent, epidemic strain has been associated with the changing epidemiology and severity of disease. Here, we review the characteristics of the epidemic NAP1, PCR ribotype 027 C. difficile strain that could explain its hypervirulence and epidemic spread. (C) 2009 Elsevier B. V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:S24 / S28
页数:5
相关论文
共 61 条
[1]   Antecedent use of fluoroquinolones is associated with resistance to moxifloxacin in Clostridium difficile [J].
Ackermann, G ;
Tang-Feldman, YJ ;
Schaumann, R ;
Henderson, JP ;
Rodloff, AC ;
Silva, J ;
Cohen, SH .
CLINICAL MICROBIOLOGY AND INFECTION, 2003, 9 (06) :526-530
[2]   Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic Clostridium difficile strains in the Cecal contents of mice [J].
Adams, Daniel A. ;
Riggs, Michelle M. ;
Donskey, Curtis J. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (08) :2674-2678
[3]   Increased sporulation rate of epidemic clostridium difficile type 027/NAP1 [J].
Akerlund, Thomas ;
Persson, Ingela ;
Unemo, Magnus ;
Noren, Torbjoern ;
Svenungsson, Bo ;
Wullt, Marlene ;
Burman, Lars G. .
JOURNAL OF CLINICAL MICROBIOLOGY, 2008, 46 (04) :1530-1533
[4]   Prevalence and pathogenicity of Clostridium difficile in hospitalized patients - A french multicenter study [J].
Barbut, F ;
Corthier, G ;
Charpak, Y ;
Cerf, M ;
Monteil, H ;
Fosse, T ;
Trevoux, A ;
DeBarbeyrac, B ;
Boussougant, Y ;
Tigaud, S ;
Tytgat, F ;
Sedallian, A ;
Duborgel, S ;
Collignon, A ;
LeGuern, ME ;
Bernasconi, P ;
Petit, JC .
ARCHIVES OF INTERNAL MEDICINE, 1996, 156 (13) :1449-1454
[5]   Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains [J].
Barbut, F ;
Decré, D ;
Lalande, V ;
Burghoffer, A ;
Noussair, L ;
Gigandon, A ;
Espinasse, F ;
Raskine, L ;
Robert, J ;
Mangeol, A ;
Branger, C ;
Petit, JC .
JOURNAL OF MEDICAL MICROBIOLOGY, 2005, 54 (02) :181-185
[6]   Effect of amoxicillin-clavulanic acid on human fecal flora in a gnotobiotic mouse model assessed with fluorescence hybridization using group-specific 16S rRNA probes in combination with flow cytometry [J].
Barc, MC ;
Bourlioux, F ;
Rigottier-Gois, L ;
Charrin-Sarnel, C ;
Janoir, C ;
Boureau, H ;
Doré, JL ;
Collignon, A .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (04) :1365-1368
[7]  
Bartlett J G, 1977, Adv Intern Med, V22, P455
[8]   Narrative review: The new epidemic of clostridium difficile-associated enteric disease [J].
Bartlett, John G. .
ANNALS OF INTERNAL MEDICINE, 2006, 145 (10) :758-764
[9]   Binding of Clostridium difficile surface layer proteins to gastrointestinal tissues [J].
Calabi, E ;
Calabi, F ;
Phillips, AD ;
Fairweather, NF .
INFECTION AND IMMUNITY, 2002, 70 (10) :5770-5778
[10]   Molecular characterization of the surface layer proteins from Clostridium difficile [J].
Calabi, E ;
Ward, S ;
Wren, B ;
Paxton, T ;
Panico, M ;
Morris, H ;
Dell, A ;
Dougan, G ;
Fairweather, N .
MOLECULAR MICROBIOLOGY, 2001, 40 (05) :1187-1199